source
- J&J to acquire Firefly Bio for $1 billion, adding degrader-antibody conjugate technologyJ&J announced it will acquire biotech startup Firefly Bio in an all‑cash transaction valued at $1 billion. The deal gives J&J access to Firefly’s degrader‑antibody conjugate platform, which blends…
- Treeline Biosciences to go public via reverse merger with Standard BioTools, securing runway to 2029Treeline Biosciences announced that it will become a publicly traded company through a reverse merger with Standard BioTools. The transaction is expected to list the combined entity on a U.S. excha…